We present a woman aged 50 years who underwent a Tru-cut biopsy for a BI-RADS 4 lesion on her right breast and received a histopathology diagnosis of a fibroadenoma. In her one year follow-up, the lesion had progressed and she underwent an excisional biopsy. Her final diagnosis was a periductal stromal tumor. Periductal stromal tumor is an extremely rare and different entity from phylloides tumor, which makes appropriate diagnosis difficult in Tru-cut biopsy and care should be taken. Lesion progression of should require a re-biopsy. Their tendency to recur warrants follow-up. We believe that radiologic, pathologic, and clinical correlation is key in decision-making and diagnosis of these tumors.
Introduction
Periductal stromal tumor (PST) is an extremely rare, low-grade neoplasm that arises from breast connective tissue. It has biphasic morphology with benign ducts and a sarcomatous stroma with no specific clinical or radiologic findings, which makes it difficult to diagnose (1) (2) (3) (4) . It was classified as a different entity by the World Health Organization (WHO) in 2002 because of lack of phylloides architecture. PST has a tendency to recur if excised incompletely and can be transformed to sarcomas, which is why surgery with safe margins is recommended (2, 3, 5) . Herein, we present the radiologic features and histopathology of this case especially to emphasize the importance of diagnosis using Tru-cut biopsy with radiologic-pathologic correlation, and to discuss the differential diagnosis of periductal stromal tumor of the breast.
Case Presentation
A woman aged 50 years who has yearly mammography screening had a new mass in her mammogram. Her mammogram showed a mass of 7 mm at its widest diameter in the upper inner quadrant of the right breast, which did not exist on her prior mammograms (Figure 1a) . The mass was oval with circumscribed margins and showed equal density. An ultrasound (USG) examination showed an oval mass in parallel orientation with circumscribed margins in the upper inner quadrant of the right breast. The mass was 6.8 x 6.0 mm in size (Figure 1b) . The lesion was de novo and interpreted as BIRADS 4a and a biopsy was recommended. A Tru-cut biopsy was performed and interpreted as fibroadenoma with intraductal hyperplasia by an external pathology clinic. One year later, her routine screening mammogram showed indistinct margins (Figure 1c) . A USG examination showed similar features to the prior examination but the size had enlarged to 9.0 x 7.5 mm (Figure 1d) . Rebiopsy of the lesion was planned. Reinterpretation of her prior biopsy specimen showed a tumor with biphasic proliferation with minimal atypical spindle cells that surrounded open ducts and tubules with lack of leaf-like growth pattern. A multidisciplinary breast board recommended an excisional biopsy depending on the new interpretation and enlargement of the lesion. An excisional biopsy after guide-wire localization was performed. Excisional biopsy 13 months after the first Tru-cut biopsy showed a 70 x 60 x 30 mm specimen; by multiple sectioning, lobulated lesion that was a beige in color and 8 mm in diameter. The lesion was 5 mm distant to the nearest surgical margin. 
Discussion and Conclusion
Periductal stromal tumor was previously accepted as a synonym for phylloides tumor, but it was recently classified as a distinct entity by the WHO in 2002 because of lack of leaf-like growth pattern (1, 2) . Unlike phylloides tumor, the incidence is higher in perimenopausal and post-menopausal women. Similar to phylloides tumor, it has a tendency for local recurrence when incompletely excised and can transform to sarcomas (2). Histologically, it has a biphasic prolifera- In differential diagnosis several tumors should be thought; firstly phylloides tumor, then spindle cell carcinoma, myoepithelial carcinoma and other breast sarcomas (1). The main difference from phylloides tumor is the lack of leaf-like pattern in PST. The differential diagnosis of spindle cell carcinoma is important because of different targeted therapy and immunohistochemistry can also be helpful; tumor cells are positive with CK5, CK14, p63, and negative with CD34 (8-10). Breast sarcomas have highly pleomorphic nuclei, abundant mitotic figures, and positive with CD10 and Vimentin, and negative with CD34. Myoepithelial carcinomas have an infiltrative growth pattern with biphasic or glandular pattern, are highly pleomorphic, mitotically active, and positive for Vimentin, SMA, S100, p63 and CK14 (1, 10) . In the present case, tumor composed of minimal atypical spindle cells surrounded open ducts and tubules without a leaf-like growth pattern. Spindle cells were only positive with CD10 and CD34, and the proliferation index was 1%, which was compatible with PST.
As a result, PST is an extremely rare entity, and shows similar symptoms with other benign and malignant breast tumors, absence of specific radiologic findings make the diagnosis difficult (2). Extensive tumor sampling and additional immunohistochemistry should be performed for appropriate diagnosis. Before making a decision, other spindle cell tumors should be taken in consideration in the differential diagnosis because of different targeted therapy.
There are few case reports published in the English literature because PST is a rare entity (3, (11) (12) (13) . There is little information about the radiologic features of these lesions; the only two separate cases reported in the literature roughly describe the radiologic features without using definitive images (12, 13) . Although the descriptions and images are not clear in these reports, the lesions seem to have similar radiologic features (12, 13) . The radiologic features of our case were similar to a fibroadenoma. However, de novo presentation after middle age and enlargement during follow-up should raise suspicion in such cases. To our knowledge, this is the first detailed report of PST with USG and mammographic findings.
We believe that radiologic, pathologic, and clinical correlation are key in decision making and the diagnosis of these tumors.
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